Gilenya may also be prescribed to treat clinically isolated syndrome (CIS). People with CIS often (but not always) develop MS later on. If you and your doctor agree that Gilenya is working well for ...

If you have a certain type of multiple sclerosis (MS), your doctor might suggest Gilenya (fingolimod) as a treatment option for you. Gilenya is a prescription medication that’s used to treat the ...

After back-to-back setbacks in its high-stakes Gilenya patent defense, Novartis is taking its arguments all the way to the Supreme Court. Wednesday, Novartis said it plans to petition the Supreme ...

Novartis has confirmed the latest global patient-use data which showed that Gilenya (fingolimod) has been used to treat more than 63,000 patients in clinical trials and the post-marketing setting.

Novartis got a reprieve last week when the U.S. Patent and Trademark Office upheld a patent on its multiple sclerosis blockbuster Gilenya. Now, the Swiss pharma intends to use that win in court ...

The Food and Drug Administration is investigating a reported case of the brain infection progressive multifocal leukoencephalopathy in a patient taking the Novartis MS drug Gilenya in Europe. The ...

The FDA has approved Gilenya (fingolimod capsules, from Novartis), a sphingosine 1-phosphate receptor modulator indicated for the treatment of patients with relapsing forms of multiple sclerosis to ...

ZURICH, March 21 (Reuters) - Swiss drugmaker Novartis AG said the European Commission approved its multiple sclerosis pill Gilenya, a potential blockbuster that should help it cope with price ...

(CBS/AP) The FDA has green-lighted the first oral medication for multiple sclerosis. Gilenya treats the underlying causes of MS, a debilitating nervous system disorder that has traditionally been ...

ZURICH, Dec 12 (Reuters) - Swiss drugmaker Novartis said on Monday it was investigating whether its multiple sclerosis pill Gilenya, a potential blockbuster, caused the death of a 59-year-old patient ...

Novartis AG’s multiple sclerosis pill Gilenya will cost 1,850 euros ($2,645) for 28 days in Germany, according to a company spokesman. Novartis has set an annual wholesale price of about 24,000 euros ...